Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Birth Control Methods01:22

Birth Control Methods

Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although vasectomy...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Proliferative Phase01:20

Proliferative Phase

The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The risk of thromboembolism and use of combined oral contraceptives: a comment.

BJOG : an international journal of obstetrics and gynaecology·2023
Same author

[Contraception in Women at Risk].

Therapeutische Umschau. Revue therapeutique·2022
Same author

[Menopausal Hormone Therapy in women with other underlying diseases: how to proceed?]

Therapeutische Umschau. Revue therapeutique·2021
Same author

Therapeutische Umschau. Revue therapeutique·2021
Same author

[Climacteric depression and anxiety].

Therapeutische Umschau. Revue therapeutique·2021
Same author

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO.

Swiss medical weekly·2017

Related Experiment Video

Updated: Jun 26, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

[Progestagen use in oral contraception - basic knowledge].

Martin Birkhäuser1

  • 1Abteilung für gynäkologische Endokrinologie und Reproduktionsmedizin, Frauenklinik, Universitätsspital Bern. martin.birkhaeuser@balcab.ch

Therapeutische Umschau. Revue Therapeutique
|January 31, 2009
PubMed
Summary

Progestagens used in hormone replacement therapy and contraception have varied effects due to differences in structure and metabolism. Newer progestagens like Dienogest and Drospirenone offer favorable profiles for specific clinical applications.

More Related Videos

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

Related Experiment Videos

Last Updated: Jun 26, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

Area of Science:

  • Pharmacology
  • Endocrinology
  • Reproductive Medicine

Background:

  • Progestagens are key components in hormone replacement therapy (HRT) and hormonal contraception.
  • Existing progestagens exhibit diverse pharmacokinetic and pharmacodynamic properties.
  • A unified classification of progestagens overlooks individual variations and clinical implications.

Purpose of the Study:

  • To review the distinct properties and partial activities of currently used progestagens.
  • To analyze the clinical consequences arising from these differences.
  • To highlight newer progestagens with favorable metabolic profiles.

Main Methods:

  • Comprehensive literature review of progestagen pharmacology and clinical applications.
  • Comparative analysis of progestagen structure, metabolism, bioavailability, and partial activities.
  • Evaluation of clinical outcomes associated with specific progestagen use in HRT, contraception, and anti-androgen therapy.

Main Results:

  • Progestagens are not a homogenous class; significant variations exist in their effects.
  • Differences in structure and metabolism lead to distinct clinical profiles.
  • Norpregnanes, Dienogest, and Drospirenone demonstrate favorable metabolic profiles and specific therapeutic advantages.

Conclusions:

  • Clinical applications of progestagens should be tailored based on their individual properties.
  • Understanding progestagen profiles is crucial for optimizing HRT and contraception.
  • Newer progestagens offer improved therapeutic options due to their specific characteristics.